TaiMed Biologics Inc. (4147.TWO)
TWD 82.5
(-0.48%)
TWD 82.5
(-0.48%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 499.84 Million TWD | 1.59% |
| 2022 | 492.03 Million TWD | 3032.95% |
| 2021 | 15.7 Million TWD | 653.19% |
| 2020 | -2.83 Million TWD | 99.11% |
| 2019 | -318.93 Million TWD | 45.58% |
| 2018 | -586.09 Million TWD | 65.47% |
| 2017 | -1.69 Billion TWD | 14.64% |
| 2016 | -1.98 Billion TWD | -7.0% |
| 2015 | -1.85 Billion TWD | -355.99% |
| 2014 | -407.46 Million TWD | -493.7% |
| 2013 | -68.63 Million TWD | 86.52% |
| 2012 | -509.27 Million TWD | 18.43% |
| 2011 | -624.32 Million TWD | 18.23% |
| 2010 | -763.49 Million TWD | -182.65% |
| 2009 | -270.12 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.11 Billion TWD | -324.03% |
| 2024 Q2 | -79.04 Million TWD | 92.94% |
| 2023 Q4 | 499.84 Million TWD | 1.6% |
| 2023 Q1 | 539.73 Million TWD | 9.7% |
| 2023 FY | 499.84 Million TWD | 1.59% |
| 2023 Q3 | 491.98 Million TWD | 20.81% |
| 2023 Q2 | 407.24 Million TWD | -24.55% |
| 2022 Q2 | 446.73 Million TWD | 418.92% |
| 2022 Q1 | 86.08 Million TWD | 448.16% |
| 2022 FY | 492.03 Million TWD | 3032.95% |
| 2022 Q4 | 492.03 Million TWD | 14.94% |
| 2022 Q3 | 428.08 Million TWD | -4.17% |
| 2021 Q4 | 15.7 Million TWD | -70.26% |
| 2021 Q2 | 101.66 Million TWD | -37.45% |
| 2021 Q1 | 162.52 Million TWD | 5824.73% |
| 2021 Q3 | 52.79 Million TWD | -48.06% |
| 2021 FY | 15.7 Million TWD | 653.19% |
| 2020 Q3 | 174.91 Million TWD | 349.73% |
| 2020 FY | -2.83 Million TWD | 99.11% |
| 2020 Q1 | -246.71 Million TWD | 22.65% |
| 2020 Q2 | -70.04 Million TWD | 71.61% |
| 2020 Q4 | -2.83 Million TWD | -101.62% |
| 2019 Q4 | -318.93 Million TWD | 60.91% |
| 2019 FY | -318.93 Million TWD | 45.58% |
| 2019 Q1 | -477.21 Million TWD | 18.58% |
| 2019 Q2 | -436.14 Million TWD | 8.6% |
| 2019 Q3 | -816 Million TWD | -87.09% |
| 2018 FY | -586.09 Million TWD | 65.47% |
| 2018 Q4 | -586.09 Million TWD | 36.1% |
| 2018 Q3 | -917.22 Million TWD | 23.32% |
| 2018 Q2 | -1.19 Billion TWD | 21.11% |
| 2018 Q1 | -1.51 Billion TWD | 10.66% |
| 2017 FY | -1.69 Billion TWD | 14.64% |
| 2017 Q4 | -1.69 Billion TWD | -18.15% |
| 2017 Q3 | -1.43 Billion TWD | 12.6% |
| 2017 Q2 | -1.64 Billion TWD | 7.9% |
| 2017 Q1 | -1.78 Billion TWD | 10.24% |
| 2016 Q3 | -1.79 Billion TWD | 0.66% |
| 2016 Q1 | -1.85 Billion TWD | -0.07% |
| 2016 FY | -1.98 Billion TWD | -7.0% |
| 2016 Q4 | -1.98 Billion TWD | -10.69% |
| 2016 Q2 | -1.8 Billion TWD | 2.76% |
| 2015 Q3 | -433.31 Million TWD | -1.96% |
| 2015 FY | -1.85 Billion TWD | -355.99% |
| 2015 Q4 | -1.85 Billion TWD | -328.79% |
| 2015 Q2 | -424.98 Million TWD | -31.09% |
| 2015 Q1 | -324.17 Million TWD | 20.44% |
| 2014 Q2 | -477.97 Million TWD | -241.36% |
| 2014 Q4 | -407.46 Million TWD | 0.0% |
| 2014 Q1 | 338.13 Million TWD | 592.68% |
| 2014 FY | -407.46 Million TWD | -493.7% |
| 2013 Q1 | -69.25 Million TWD | 86.4% |
| 2013 Q2 | -69.25 Million TWD | 0.0% |
| 2013 Q3 | -68.63 Million TWD | 0.9% |
| 2013 Q4 | -68.63 Million TWD | 0.0% |
| 2013 FY | -68.63 Million TWD | 86.52% |
| 2012 Q3 | -73.17 Million TWD | 87.4% |
| 2012 Q2 | -580.53 Million TWD | 0.0% |
| 2012 Q4 | -509.27 Million TWD | -596.0% |
| 2012 FY | -509.27 Million TWD | 18.43% |
| 2011 FY | -624.32 Million TWD | 18.23% |
| 2011 Q2 | -694.47 Million TWD | 0.0% |
| 2011 Q4 | -624.32 Million TWD | 0.0% |
| 2010 Q4 | -763.49 Million TWD | 0.0% |
| 2010 FY | -763.49 Million TWD | -182.65% |
| 2009 FY | -270.12 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bio Preventive Medicine Corp. | 31.8 Million TWD | -1471.404% |
| Genomics BioSci & Tech. Co.,Ltd. | 30.57 Million TWD | -1534.665% |
| Advagene Biopharma Co., Ltd. | -64.32 Million TWD | 877.115% |
| Taiwan Bio Therapeutics Co., Ltd | 20.48 Million TWD | -2340.307% |
| NaviFUS Corp. | -123.12 Million TWD | 505.955% |
| G&E Herbal Biotechnology Co., Ltd. | -134.25 Million TWD | 472.321% |
| TaiRx, Inc. | -147.86 Million TWD | 438.034% |
| Sinew Pharma Inc. | -160.34 Million TWD | 411.733% |
| Lin BioScience, Inc. | -3.21 Billion TWD | 115.532% |
| TaiwanJ Pharmaceuticals Co., Ltd. | -57.65 Million TWD | 966.919% |
| Lumosa Therapeutics Co., Ltd. | -412.63 Million TWD | 221.135% |
| Anti-Microbial Savior BioteQ Co., Ltd | -77.04 Million TWD | 748.783% |
| SYN-TECH Chem. & Pharm. Co., Ltd. | -264.16 Million TWD | 289.215% |
| AP Biosciences Inc | -196.52 Million TWD | 354.339% |
| Sunmax Biotechnology Co., Ltd. | -680.6 Million TWD | 173.442% |
| RBC Bioscience Corporation | 422.18 Million TWD | -18.395% |
| Syngen Biotech Co.,Ltd. | 314.87 Million TWD | -58.746% |
| EirGenix Inc. | -4.58 Billion TWD | 110.895% |
| Enimmune corporation | -314.15 Million TWD | 259.107% |
| Lukas Biomedical Inc. | 50.75 Million TWD | -884.825% |
| BRIM Biotechnology, Inc. | -944.4 Million TWD | 152.927% |
| 3D Global Biotech Inc. | -11.43 Million TWD | 4470.447% |
| Mycenax Biotech Inc. | 207 Million TWD | -141.462% |
| TCI GENE Inc. | -689.25 Million TWD | 172.52% |
| SynCore Biotechnology Co.,Ltd | -262.58 Million TWD | 290.359% |
| Oneness Biotech Co., Ltd. | -414.87 Million TWD | 220.481% |
| Eusol Biotech Co.,Ltd. | -209.33 Million TWD | 338.776% |
| Feng Chi Biotech Corp. | -19.81 Million TWD | 2622.828% |
| NeoCore Technology Co., Ltd. | -196.39 Million TWD | 354.509% |
| TWi Biotechnology, Inc. | -143.86 Million TWD | 447.447% |
| Neith Corporation | -150.31 Million TWD | 432.543% |
| Sunny Pharmtech Inc. | 120.87 Million TWD | -313.538% |
| VBI | -25.31 Million TWD | 2074.435% |
| Ever Supreme Bio Technology Co., Ltd | -330.54 Million TWD | 251.221% |
| GeneReach Biotechnology Corp. | 40.26 Million TWD | -1141.365% |
| Shine-On BioMedical Co.,Ltd. | -101.48 Million TWD | 592.529% |
| CHO Pharma, Inc. | -203.79 Million TWD | 345.274% |
| Andros Pharmaceuticals Co.,Ltd | -241.89 Million TWD | 306.64% |
| MegaPro Biomedical Co., Ltd | -118.93 Million TWD | 520.259% |
| Visgeneer Inc. | 31.28 Million TWD | -1497.775% |
| Greenyn Biotechnology Co., Ltd | -337.37 Million TWD | 248.158% |
| BioLASCO Taiwan Co., Ltd. | -84.76 Million TWD | 689.701% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | 74.05 Million TWD | -575.005% |
| Sagittarius Life Science Corp | -120.57 Million TWD | 514.571% |
| BioGend Therapeutics Co., Ltd. | -317.41 Million TWD | 257.473% |
| GlycoNex Incorporation | -148.56 Million TWD | 436.446% |
| Medigen Biotechnology Corp. | 688.73 Million TWD | 27.425% |
| Pharmosa Biopharm Inc. | -829.69 Million TWD | 160.245% |
| PharmaEngine, Inc. | -860.8 Million TWD | 158.067% |
| Intech Biopharm Corporation | 1.35 Billion TWD | 63.174% |
| Taiwan Advance Bio-Pharmaceutical Inc. | 137.99 Million TWD | -262.222% |
| BiOptic Inc. | 12.59 Million TWD | -3869.568% |
| TaiGen Biopharmaceuticals Holdings Limited | -299.96 Million TWD | 266.634% |
| Senhwa Biosciences, Inc. | -1.3 Billion TWD | 138.179% |
| NatureWise Biotech & Medicals Corporation | -101.87 Million TWD | 590.672% |
| OBI Pharma, Inc. | -398.22 Million TWD | 225.519% |
| Savior Lifetec Corporation | -812.54 Million TWD | 161.516% |
| Great Novel Therapeutics Biotech & Medicals | -165.17 Million TWD | 402.615% |
| Level Biotechnology Inc. | -453.9 Million TWD | 210.122% |
| Medigen Vaccine Biologics Corporation | 621.53 Million TWD | 19.579% |
| Meribank Biotech Co., Ltd | -365.41 Million TWD | 236.788% |
| Acepodia, Inc. | -6.02 Billion TWD | 108.303% |
| Caliway Biopharmaceuticals Co., Ltd. | -3.4 Billion TWD | 114.694% |